ストックスクリーナーアプリを入手
63.02
3.76%
2.455
前日終値:
$60.57
開ける：
$60.58
24時間の取引高:
2.01M
Relative Volume:
0.28
時価総額：
$25.17B
収益：
$2.23B
当期純損益:
$-3.19B
株価収益率:
-7.7367
EPS:
-8.1462
ネットキャッシュフロー:
$-1.60B
1週間 パフォーマンス:
+11.72%
1か月 パフォーマンス:
-7.94%
6か月 パフォーマンス:
+56.69%
1年 パフォーマンス:
+144.93%
1日の値動き範囲:
$59.29
$63.07
1週間の範囲:
$53.71
$62.98
52週間の値動き範囲:
$22.28
$85.60
Moderna Inc Stock (MRNA) Company Profile
Compare MRNA vs VRTX, REGN, ARGX, RVMD, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
63.04 | 24.18B | 2.23B | -3.19B | -1.60B | -8.1462 |
VRTX
Vertex Pharmaceuticals Inc
|
529.50 | 134.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
794.77 | 82.06B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
875.94 | 54.10B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.91 | 44.06B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
358.45 | 40.64B | 5.76B | 514.49M | 1.10B | 4.4813 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-28 | 再開されました | Barclays | Equal Weight |
| 2026-01-07 | 再開されました | UBS | Neutral |
| 2025-12-12 | 開始されました | Jefferies | Hold |
| 2025-03-13 | 開始されました | Citigroup | Neutral |
| 2025-02-18 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2025-01-29 | ダウングレード | Goldman | Buy → Neutral |
| 2024-12-18 | ダウングレード | Argus | Buy → Hold |
| 2024-12-10 | 再開されました | BofA Securities | Underperform |
| 2024-11-19 | 開始されました | Berenberg | Hold |
| 2024-11-18 | アップグレード | HSBC Securities | Hold → Buy |
| 2024-11-15 | 開始されました | Wolfe Research | Underperform |
| 2024-10-17 | 開始されました | Bernstein | Mkt Perform |
| 2024-09-13 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2024-09-13 | ダウングレード | Jefferies | Buy → Hold |
| 2024-09-13 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2024-08-28 | アップグレード | HSBC Securities | Reduce → Hold |
| 2024-08-07 | アップグレード | Deutsche Bank | Sell → Hold |
| 2024-08-05 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-02-26 | ダウングレード | HSBC Securities | Hold → Reduce |
| 2024-01-02 | アップグレード | Oppenheimer | Perform → Outperform |
| 2023-11-29 | 開始されました | Canaccord Genuity | Hold |
| 2023-11-03 | アップグレード | HSBC Securities | Reduce → Hold |
| 2023-11-02 | ダウングレード | Deutsche Bank | Hold → Sell |
| 2023-08-04 | ダウングレード | TD Cowen | Outperform → Market Perform |
| 2023-08-03 | ダウングレード | Deutsche Bank | Buy → Hold |
| 2023-07-24 | 開始されました | William Blair | Mkt Perform |
| 2023-07-14 | 開始されました | HSBC Securities | Reduce |
| 2023-06-26 | アップグレード | UBS | Neutral → Buy |
| 2023-04-26 | 開始されました | Guggenheim | Neutral |
| 2023-03-13 | アップグレード | TD Cowen | Market Perform → Outperform |
| 2023-03-02 | 開始されました | RBC Capital Mkts | Outperform |
| 2023-02-24 | ダウングレード | SVB Securities | Market Perform → Underperform |
| 2022-12-19 | アップグレード | Jefferies | Hold → Buy |
| 2022-12-14 | ダウングレード | Chardan Capital Markets | Buy → Neutral |
| 2022-10-21 | アップグレード | SVB Leerink | Underperform → Mkt Perform |
| 2022-09-08 | アップグレード | Deutsche Bank | Hold → Buy |
| 2022-02-01 | アップグレード | Redburn | Sell → Neutral |
| 2022-01-26 | アップグレード | Deutsche Bank | Sell → Hold |
| 2022-01-21 | アップグレード | BofA Securities | Underperform → Neutral |
| 2022-01-21 | 開始されました | UBS | Neutral |
| 2021-12-07 | 開始されました | Cowen | Market Perform |
| 2021-11-09 | 開始されました | Wolfe Research | Outperform |
| 2021-10-22 | 開始されました | Deutsche Bank | Sell |
| 2021-10-15 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2021-08-06 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2021-08-06 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2021-07-15 | 繰り返されました | Jefferies | Hold |
| 2021-02-01 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2020-12-16 | ダウングレード | Jefferies | Buy → Hold |
| 2020-12-16 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-09 | ダウングレード | Needham | Buy → Hold |
| 2020-11-23 | 開始されました | Wells Fargo | Equal Weight |
| 2020-11-17 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-08 | ダウングレード | SVB Leerink | Mkt Perform → Underperform |
| 2020-07-23 | 開始されました | SVB Leerink | Mkt Perform |
| 2020-07-20 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2020-07-13 | 開始されました | Jefferies | Buy |
| 2020-06-30 | 開始されました | Argus | Buy |
| 2020-06-08 | 開始されました | Barclays | Overweight |
| 2020-04-30 | 開始されました | BMO Capital Markets | Outperform |
| 2020-03-05 | ダウングレード | BofA/Merrill | Buy → Neutral |
| 2019-12-03 | 再開されました | BofA/Merrill | Buy |
| 2019-10-25 | 開始されました | ROTH Capital | Buy |
| 2019-04-05 | 開始されました | Chardan Capital Markets | Buy |
すべてを表示
Moderna Inc (MRNA) 最新ニュース
Bank of America Corp DE Sells 388,494 Shares of Moderna, Inc. $MRNA - MarketBeat
Could Arbutus Biopharma Corporation (ABUS) Turn its Moderna, Inc. (MRNA) Settlement Into a Lasting Biotech Advantage? - finance.yahoo.com
FDA approval of mFLUSIVA highlights Moderna’s position in mRNA market - finance.yahoo.com
Moderna, Inc. (MRNA) Stock Analysis: Navigating Potential Amidst A -14.07% Downside - DirectorsTalk Interviews
Moderna, Inc. $MRNA Shares Acquired by Contravisory Investment Management Inc. - MarketBeat
Watch RocketLab Rises on Space Interest; Moderna Moves on Flu Shot | Stock Movers - Bloomberg.com
Moderna | History, Innovation, Challenges, & Facts - Encyclopedia Britannica
Moderna, Inc. $MRNA Shares Acquired by Empowered Funds LLC - MarketBeat
Moderna jumps as FDA flu-shot approval reinforces recent business momentum - Quiver Quantitative
FAQ: What mFLUSIVA's Approval May Signal for the Future of mRNA Vaccine Development - BioPharm International
Rule 10b5-1 plan drives Moderna, Inc. (NASDAQ: MRNA) CEO stock sales - Stock Titan
Moderna mRNA flu shot wins FDA approval but awaits CDC recommendations - Pharmaceutical Technology
Moderna (MRNA) Wins FDA Flu Vaccine Approval On Questions Over Whether The Stock Is Fully Valued - simplywall.st
Moderna Q2 Earnings Call Highlights Cost Cuts and Pipeline Milestones - finance.yahoo.com
Moderna Inc. Stock Climbs 9.9%, Outperforms Peers - Bitget
For Moderna’s Greenlit mRNA Flu Vaccine, Payoff Is a Ways Off - finance.yahoo.com
What Moderna is and how it built its mRNA vaccine platform - qz.com
FDA Approves New, More Effective Flu Vaccine From Moderna - People.com
Expert available: FDA approves 1st mRNA flu shot, from Moderna | Newswise - Newswise
Moderna Gets FDA Approval for mRNA Flu Vaccine, But CDC Input Still Uncertain - MedCity News
Opinion | The FDA, Replimune and a New Flu Shot - WSJ
FDA approves Moderna’s mFlu vaccine for adults 50 and older - CBS News
Here’s what the first mRNA flu vaccine could mean for flu season - Science News
The flu shot finally gets an upgrade - vox.com
Moderna Stock Flashing Intriguing ‘Buy The Dip’ Signal - Forbes
Moderna shares slide despite mFlusiva success 📉 What's next for the mRNA vaccines market giant? - XTB.com
MRNA Stock Gets a Shot in the Arm as FDA Approves Moderna Flu Vaccine - finance.yahoo.com
FDA approved Moderna's mRNA flu vaccine after initially refusing to review it - qz.com
Moderna wins FDA approval for first mRNA-based flu shot - americanbazaaronline.com
Moderna Just Got FDA Clearance for Flu Vaccine. The Stock Is Sliding. - Barron's
FDA approves Moderna mRNA flu shot - CNBC
FDA Approves mFLUSIVA, First mRNA-Based Flu Vaccine - Drug Topics
Beyond COVID: Moderna Wins FDA Approval for Its Seasonal Flu Vaccine - benzinga.com
Moderna’s First mRNA Flu Shot Just Won FDA Approval. Now Researchers See Potential for HIV and Malaria - inc.com
Moderna's flu shot wins FDA approval after initial regulatory battle - The Business Journals
The mRNA technology behind Moderna’s Covid vaccine reaches the flu - The Guardian
FDA Approves First mRNA Flu Vaccine in Win for Moderna After Arduous Review - WSJ
Moderna’s mRNA Flu Shot Wins US Approval in FDA Turnaround - Bloomberg.com
FDA approves Moderna’s mRNA flu vaccine - Healthcare Dive
Moderna Stock Climbs on Flu Vaccine Approval - Schaeffer's Investment Research
U.S. approves Moderna’s mRNA vaccine for flu—the first of its kind - Scientific American
U.S. FDA approves first mRNA flu shot from Moderna - cnbc.com
Moderna’s flu shot crosses FDA finish line, bouncing back from regulatory roadblock - BioSpace
FDA approves first mRNA flu vaccine - The Hill
Edgestream Partners L.P. Sells 28,698 Shares of Moderna, Inc. $MRNA - MarketBeat
Moderna, Inc. (NASDAQ:MRNA) Given Average Recommendation of "Reduce" by Analysts - MarketBeat
FDA approves Moderna's mRNA seasonal flu vaccineABC News - ABC News - Breaking News, Latest News and Videos
Moderna receives FDA approval for first mRNA flu vaccine - Investing.com
Moderna's mFlusiva Approved as First mRNA-Based Influenza VaccineMPR - Medical Professionals Reference
Moderna gains approval of first-ever mRNA flu vaccine - Seeking Alpha
FDA approves Moderna's mRNA flu vaccine after initial pushback - CBS News
Moderna Inc (MRNA) 財務データ
収益
当期純利益
現金流量
EPS
Moderna Inc (MRNA) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Bancel Stephane | Chief Executive Officer |
Aug 06 '26 |
Option Exercise |
19.15 |
252,469 |
4,834,781 |
6,440,260 |
| Bancel Stephane | Chief Executive Officer |
Aug 05 '26 |
Sale |
57.52 |
499,246 |
28,715,011 |
6,187,791 |
1.92%
0.03%
大文字化:
|
ボリューム (24 時間):